HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consumer Products Drive B+L Sales As Spinout Expenses, Increasing Costs Drag Results

Executive Summary

Consumer health products account for majority of vision care sales during Q4 and all 2022, with launch of Lumify eye drops in Canada a key driver. “While consumers have faced pressure from higher inflation and potential economic uncertainty, we have not seen broad, fundamental changes in the segment,” says CFO Sam Eldessouky.

You may also be interested in...

Bausch Health's Securities Litigation Casts Shadow Over B+L's Future As Independent Firm

For all B+L has going for it, including consumer health eye health and vision care products as its sales driver, it could be stymied by investors alleging Bausch Health conducted fraudulent conveyance by spinning out B+L through an IPO in 2022.

Bausch + Lomb Turns To Familiar Face As CEO, Brent Saunders

Saunders will oversee the consumer health, pharma and medtech eye health and vision care specialist, returning to where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.

Lumify Reaches Canada As Consumer Health Leads Sales In Bausch + Lomb's Debut Quarter

Lumify sales grew reported 21% to brand-record $35m in Q2, Bausch + Lomb’s first quarter since separating from Bausch Health through an IPO in May.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts